Close
CDMO Safety Testing 2026
Novotech

Press Releases

State of Ohio International Trade Assistance Center at YSU Assists NanoLogix with Foreign Distribution Agreements

NanoLogix Inc. an innovator in the rapid detection identification and determination of antibiotic resistance and sensitivity of live bacteria announces that the State of Ohio Department of Economic Development’s International Trade Assistance Center (ITAC) based at Youngstown State University...

Domain Therapeutics opens a North American subsidiary at Montreal’s NEOMED Institute

Strasbourg, France and Montreal, Canada, January 20, 2014 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the opening of its North American...

Otsuka Pharmaceutical’s POCARI SWEAT to Be Official Drink for Two Consecutive Asian Games

Otsuka Pharmaceutical Co. Ltd. (Head office: Chiyoda-ku Tokyo; President Representative Director: Taro Iwamoto) signed a partnership agreement with the Olympic Council of Asia (OCA) for the 2014 Incheon Asian Games (Korea) and the 2019 Hanoi Asian Games (Vietnam) during...

Arcadia Biosciences Licenses Water Use Efficiency Technology to Genective

Arcadia Biosciences Inc. and Genective S.A. a joint venture between Group LIMAGRAIN and Group KWS today announced that they have signed an agreement that will allow Genective to develop new corn hybrids incorporating Arcadia’s Water Use Efficiency (WUE) technology....

Adocia strengthens its diabetic foot ulcer patent portfolio

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic molecules, in particular proteins and oncologic drugs, announces today that it has been granted two patents. The first patent is...

TxCell to present an innovative, personalized cell-based immunotherapy approach at Biotech Showcase™ 2014, San Francisco, USA

TxCell SA, a clinical stage biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that Damian Marron, CEO, TxCell, will present at Biotech Showcase™ 2014, taking place January...

Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin

Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, in particular proteins and oncologic treatments, launches today a phase IIa clinical trial on its ultra-fast acting formulation of insulin Lispro (Humalog(R),...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »